[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100614791":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":23,"locations":29,"responsibleParty":123,"collaborators":11,"id":125,"slug":126,"hasResults":127,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":11,"eligibilityCriteria":131,"healthyVolunteers":127,"sex":132,"minAge":133,"maxAge":11,"enrollmentInfo":134,"targetDuration":11,"studyType":137,"phases":138,"briefSummary":140,"conditions":141,"keywords":11,"overallStatus":32,"whyStopped":11,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":161},{"fullName":5,"class":6},"Plexium, Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"PLX-61639","EXPERIMENTAL",null,[13],"Drug: PLX-61639",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":11},"DRUG","Orally available degrader of SMARCA2",[9],[20],{"name":21,"affiliation":5,"role":22},"Chief Medical Officer","STUDY_DIRECTOR",[24],{"name":25,"role":26,"phone":27,"phoneExt":11,"email":28},"Clinical Operations","CONTACT","619-631-3091","ClinicalTrials@Plexium.com",[30,44,53,61,70,79,87,96,105,114],{"facility":31,"status":32,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":11},"Research Site","RECRUITING","Scottsdale","Arizona","85258","United States","US",{"type":39,"coordinates":40},"Point",[41,42],-111.89903,33.50921,{"lat":42,"lon":41},{"facility":31,"status":32,"city":45,"state":46,"zip":47,"country":36,"countryCode":37,"cosmosGeoPoint":48,"geoPoint":52,"contacts":11},"Duarte","California","91010",{"type":39,"coordinates":49},[50,51],-117.97729,34.13945,{"lat":51,"lon":50},{"facility":31,"status":32,"city":54,"state":46,"zip":55,"country":36,"countryCode":37,"cosmosGeoPoint":56,"geoPoint":60,"contacts":11},"Orange","92868",{"type":39,"coordinates":57},[58,59],-117.85311,33.78779,{"lat":59,"lon":58},{"facility":31,"status":32,"city":62,"state":63,"zip":64,"country":36,"countryCode":37,"cosmosGeoPoint":65,"geoPoint":69,"contacts":11},"Boston","Massachusetts","02114",{"type":39,"coordinates":66},[67,68],-71.05977,42.35843,{"lat":68,"lon":67},{"facility":31,"status":32,"city":71,"state":72,"zip":73,"country":36,"countryCode":37,"cosmosGeoPoint":74,"geoPoint":78,"contacts":11},"St Louis","Missouri","63110",{"type":39,"coordinates":75},[76,77],-90.19789,38.62727,{"lat":77,"lon":76},{"facility":31,"status":32,"city":80,"state":80,"zip":81,"country":36,"countryCode":37,"cosmosGeoPoint":82,"geoPoint":86,"contacts":11},"New York","10044",{"type":39,"coordinates":83},[84,85],-74.00597,40.71427,{"lat":85,"lon":84},{"facility":31,"status":32,"city":88,"state":89,"zip":90,"country":36,"countryCode":37,"cosmosGeoPoint":91,"geoPoint":95,"contacts":11},"Durham","North Carolina","27710",{"type":39,"coordinates":92},[93,94],-78.89862,35.99403,{"lat":94,"lon":93},{"facility":31,"status":32,"city":97,"state":98,"zip":99,"country":36,"countryCode":37,"cosmosGeoPoint":100,"geoPoint":104,"contacts":11},"Cleveland","Ohio","44106",{"type":39,"coordinates":101},[102,103],-81.69541,41.4995,{"lat":103,"lon":102},{"facility":31,"status":32,"city":106,"state":107,"zip":108,"country":36,"countryCode":37,"cosmosGeoPoint":109,"geoPoint":113,"contacts":11},"San Antonio","Texas","78229",{"type":39,"coordinates":110},[111,112],-98.49363,29.42412,{"lat":112,"lon":111},{"facility":31,"status":32,"city":115,"state":116,"zip":117,"country":36,"countryCode":37,"cosmosGeoPoint":118,"geoPoint":122,"contacts":11},"Fairfax","Virginia","22031",{"type":39,"coordinates":119},[120,121],-77.30637,38.84622,{"lat":121,"lon":120},{"type":124,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100614791","phase-1-first-in-human-study-of-plx-61639-in-locally-advanced-or-metastatic-solid-tumors-100614791",false,"NCT07284186","First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors","A Phase 1, First-in-Human Study of the SMARCA2 Degrader, PLX-61639, in Patients With SMARCA4-Mutated Locally Advanced or Metastatic Solid Tumors","Key Inclusion Criteria:\n\n* Participants with locally advanced or metastatic, relapsed\u002Frefractory, solid tumors harboring a SMARCA4 loss-of-function mutation that have progressed on, are intolerant of, or not otherwise candidates for available approved therapies\n* Adequate liver bone marrow, coagulation, renal, and cardiopulmonary function\n* Measurable disease per RECIST 1.1\n* ECOG PS of 0 or 1\n\nKey Exclusion Criteria:\n\n* Germline SMARCA4 mutations\n* Known SMARCA2 mutation or loss of expression\n* Symptomatic CNS disease\n* Prior treatment with another SMARCA2-directed therapy\n* History of other malignancies\n* Clinically significant heart disease\n* Uncontrolled hypertension\n* Prolongation of QT interval","ALL","18 Years",{"count":135,"type":136},155,"ESTIMATED","INTERVENTIONAL",[139],"PHASE1","A multicenter, single-arm, first-in-human study to investigate the safety, pharmacokinetics, and preliminary antitumor activity of PLX-61639 in participants with locally advanced or metastatic, relapsed\u002Frefractory, SMARCA4-deficient solid tumors who are intolerant of or have failed available, approved therapies.\n\nThe study will be conducted in 3 parts: dose escalation (Part 1), dose optimization (Part 2), and cohort expansion (Part 3). Each part of the study will consist of a Screening Phase lasting up to 28 days during which participants will be assessed for eligibility, a Treatment Phase beginning on Cycle 1 Day 1 and consisting of consecutive 28-day cycles, an End of Treatment Visit, and a Post-Treatment Follow-Up Phase.\n\nParticipants will receive their assigned dose of PLX-61639 administered orally, once daily until progression\u002Frelapse, intolerance, death, or withdrawal from study treatment by the Investigator or participant.",[142,143,144,145,146,147,148,149,150,151],"Esophageal Squamous Cell Carcinoma","Gastric Adenocarcinoma","Gastric Squamous Cell Carcinoma","Gastroesophageal Junction (GEJ) Adenocarcinoma","Metastatic Solid Tumor","Non-Small Cell Lung Carcinoma","Esophageal Adenocarcinoma","SMARCA4 Mutation","Gastroesophageal Junction Squamous Cell Carcinoma","Advanced Solid Tumor","2026-06-10",{"date":154,"type":155},"2026-06-12","ACTUAL",{"date":157,"type":155},"2025-12-01",{"date":159,"type":136},"2030-09",{"name":5,"class":6},10]